{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:03:23Z","timestamp":1791597803342,"version":"4.3.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"39","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016186","name":"DalCor Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1\u20133 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600\u2005mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6%) of 3076 patients in the placebo group [hazard ratio 0.88; 95% confidence interval (CI) 0.75\u20131.03; P = 0.12]. The hazard ratios for the components of the primary endpoint were 0.79 (95% CI 0.65\u20130.96) for myocardial infarction, 0.92 (95% CI 0.64\u20131.33) for stroke, 1.21 (95% CI 0.91\u20131.60) for death from cardiovascular causes, and 2.33 (95% CI 0.60\u20139.02) for resuscitated cardiac arrest. In a pre-specified on-treatment sensitivity analysis, the primary endpoint event rate was 7.8% (236\/3015) in the dalcetrapib group and 9.3% (282\/3031) in the placebo group (hazard ratio 0.83; 95% CI 0.70\u20130.98).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Dalcetrapib did not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events at end of study. A new trial would be needed to test the pharmacogenetic hypothesis that dalcetrapib improves the prognosis of patients with the AA genotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>Trial registration dal-GenE ClinicalTrials.gov Identifier: NCT02525939<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac374","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T13:19:05Z","timestamp":1658323145000},"page":"3947-3956","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-8983","authenticated-orcid":false,"given":"Jean Claude","family":"Tardif","sequence":"first","affiliation":[{"name":"Department of Medicine, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, PQ, H1T1C8 Canada"},{"name":"Beaulieu-Saucier Pharmacogenomics Centre, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"},{"name":"The Montreal Health Innovations Coordinating Center (MHICC), Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kouz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre Hospitalier R\u00e9gional de Lanaudi\u00e8re , Joliette , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen , Munich , Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich , Germany"},{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm , Ulm , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo P","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"Department of Medicine, British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mooser","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-8198","authenticated-orcid":false,"given":"David D","family":"Waters","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Francisco General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean C","family":"Gr\u00e9goire","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, PQ, H1T1C8 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L","family":"L\u2019Allier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, PQ, H1T1C8 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-8359","authenticated-orcid":false,"given":"J","family":"Wouter Jukema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Leiden , The Netherlands"},{"name":"Netherlands Heart Institute , Utrecht , The Netherlands"},{"name":"Department of Medicine, Durrer Center for Cardiovascular Research , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Unit, Auckland City Hospital, University of Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Heinonen","sequence":"additional","affiliation":[{"name":"DalCor Pharmaceuticals , Montreal , Canada"},{"name":"DalCor Pharmaceuticals , Sarasota, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M","family":"Black","sequence":"additional","affiliation":[{"name":"DalCor Pharmaceuticals , Montreal , Canada"},{"name":"DalCor Pharmaceuticals , Sarasota, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Laghrissi-Thode","sequence":"additional","affiliation":[{"name":"DalCor Pharmaceuticals , Montreal , Canada"},{"name":"DalCor Pharmaceuticals , Sarasota, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Levesque","sequence":"additional","affiliation":[{"name":"The Montreal Health Innovations Coordinating Center (MHICC), Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claude","family":"Guertin","sequence":"additional","affiliation":[{"name":"The Montreal Health Innovations Coordinating Center (MHICC), Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-4393","authenticated-orcid":false,"given":"Marie Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, PQ, H1T1C8 Canada"},{"name":"Beaulieu-Saucier Pharmacogenomics Centre, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the dal-GenE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"2022101418264649300_ehac374-B1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2022101418264649300_ehac374-B2","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1161\/ATVBAHA.116.307122","article-title":"CETP: pharmacogenomics-based response to the CETP inhibitor dalcetrapib","volume":"37","author":"Tardif","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022101418264649300_ehac374-B6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","article-title":"Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges","volume":"128","author":"Rosenson","year":"2013","journal-title":"Circulation"},{"key":"2022101418264649300_ehac374-B7","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"2022101418264649300_ehac374-B9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/CIRCGENETICS.116.001405","article-title":"Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes","volume":"9","author":"Tardif","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"2022101418264649300_ehac374-B10","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1161\/CIRCULATIONAHA.117.031134","article-title":"ADCY9 (adenylate cyclase type 9) inactivation protects from atherosclerosis only in the absence of CETP (cholesteryl ester transfer protein)","volume":"138","author":"Rautureau","year":"2018","journal-title":"Circulation"},{"key":"2022101418264649300_ehac374-B11","doi-asserted-by":"publisher","first-page":"e69198","DOI":"10.7554\/eLife.69198","article-title":"A sex-specific evolutionary interaction between ADCY9 and CETP","volume":"10","author":"Gamache","year":"2021","journal-title":"Elife"},{"key":"2022101418264649300_ehac374-B12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ahj.2020.01.007","article-title":"Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib","volume":"222","author":"Tardif","year":"2020","journal-title":"Am Heart J"},{"key":"2022101418264649300_ehac374-B13","doi-asserted-by":"publisher","first-page":"e001359","DOI":"10.1136\/openhrt-2020-001359","article-title":"The impact of the COVID-19 pandemic on cardiology services","volume":"7","author":"Fersia","year":"2020","journal-title":"BMJ Open Heart"},{"key":"2022101418264649300_ehac374-B14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","article-title":"The COVID-19 pandemic and the incidence of acute myocardial infarction","volume":"383","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","article-title":"Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022101418264649300_ehac374-B16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","article-title":"ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study","volume":"3","author":"Nissen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022101418264649300_ehac374-B17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamacardio.2018.2379","article-title":"Randomized clinical trial needed to confirm whether dalcetrapib improves outcomes for specific ADCY9 genotype","volume":"3","author":"Pfeffer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022101418264649300_ehac374-B18","article-title":"CETP inhibition and ADCY9 genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?","volume":"6","author":"Holmes","year":"2018","journal-title":"bioRxiv"},{"key":"2022101418264649300_ehac374-B19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.119.041546","article-title":"Impact of ADCY9 genotype on response to anacetrapib","volume":"140","author":"Hopewell","year":"2019","journal-title":"Circulation"},{"key":"2022101418264649300_ehac374-B20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55-REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2022101418264649300_ehac374-B21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1194\/jlr.M068940","article-title":"Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys","volume":"58","author":"Brodeur","year":"2017","journal-title":"J Lipid Res"},{"key":"2022101418264649300_ehac374-B22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/ATVBAHA.115.306680","article-title":"Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein","volume":"36","author":"Reyes-Soffer","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022101418264649300_ehac374-B23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1194\/jlr.M300198-JLR200","article-title":"Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency","volume":"45","author":"Asztalos","year":"2004","journal-title":"J Lipid Res"},{"key":"2022101418264649300_ehac374-B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MOL.0b013e3283475e00","article-title":"Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism","volume":"22","author":"Niesor","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"2022101418264649300_ehac374-B25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/fca.12.25","article-title":"An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels","volume":"8","author":"Rhainds","year":"2012","journal-title":"Future Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/39\/3947\/46536486\/ehac374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/39\/3947\/46536486\/ehac374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T21:40:23Z","timestamp":1665783623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/39\/3947\/6646961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":25,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2022,7,20]]},"published-print":{"date-parts":[[2022,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac374","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,14]]},"published":{"date-parts":[[2022,7,20]]}}}